Literature DB >> 15295051

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.

Biff F Palmer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15295051     DOI： 10.1056/NEJMra035279

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  136 in total

1.  Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals.

Authors:  Elena Ramírez; Tomás Rossignoli; Armando J Campos; Raúl Muñoz; Claudia Zegarra; Hoi Tong; Nicolás Medrano; Alberto M Borobia; Antonio J Carcas; Jesús Frías
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

2.  Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Authors:  Pantelis A Sarafidis; Rochelle Blacklock; Eleri Wood; Adam Rumjon; Shanique Simmonds; Jessica Fletcher-Rogers; Rachel Ariyanayagam; Aziza Al-Yassin; Claire Sharpe; Katie Vinen
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

3.  Aldosterone antagonists in the treatment and prevention of heart failure.

Authors:  Rebecca S Boxer; Mark E Dunlap
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

4.  Hyperkalemia associated with spironolactone therapy.

Authors:  Lisa Dolovich; Scott Gavura; Kevin Pottie
Journal:  Can Fam Physician       Date:  2005-03       Impact factor: 3.275

5.  Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.

Authors:  Jörg Indermitte; Sabine Burkolter; Jürgen Drewe; Stephan Krähenbühl; Kurt E Hersberger
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 6.  Monitoring renal function in hypertension.

Authors:  Una Martin; Jamie J Coleman
Journal:  BMJ       Date:  2006-10-28

7.  Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.

Authors:  Allan J Collins; Bertram Pitt; Nancy Reaven; Susan Funk; Karen McGaughey; Daniel Wilson; David A Bushinsky
Journal:  Am J Nephrol       Date:  2017-09-02       Impact factor: 3.754

8.  Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.

Authors:  Csaba P Kovesdy; Kunihiro Matsushita; Yingying Sang; Nigel J Brunskill; Juan J Carrero; Gabriel Chodick; Takeshi Hasegawa; Hiddo L Heerspink; Atsushi Hirayama; Gijs W D Landman; Adeera Levin; Dorothea Nitsch; David C Wheeler; Josef Coresh; Stein I Hallan; Varda Shalev; Morgan E Grams
Journal:  Eur Heart J       Date:  2018-05-01       Impact factor: 29.983

9.  Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.

Authors:  Marsha A Raebel; Colleen Ross; Stanley Xu; Douglas W Roblin; Craig Cheetham; Christopher M Blanchette; Gwyn Saylor; David H Smith
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

Review 10.  Potassium: friend or foe?

Authors:  Aylin R Rodan
Journal:  Pediatr Nephrol       Date:  2016-05-18       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.